Epilepsy is a common and devastating neurological disorder characterized by recurrent and unprovoked spontaneous seizures. One leading hypothesis for the development and progression of epilepsy is that large-scale changes in gene transcription and protein expression contribute to aberrant network restructuring and hyperexcitability, resulting in the genesis of repeated seizures. Current research shows that epigenetic mechanisms, including posttranslational alterations to the proteins around which DNA is coiled, chemical modifications to DNA, and the activity of various noncoding RNA molecules exert important influences on these gene networks in experimental epilepsy. Key findings from animal models have been replicated in humans using brain tissue obtained from living patients at the time of neurosurgical resection for pharmacoresistant epilepsy. These findings have spurred efforts to target epigenetic processes to disrupt or modify epilepsy in experimental models with varying degrees of success. In this review, we will (1) summarize the epigenetic mechanisms implicated in epileptogenesis and epilepsy, (2) explore the influence of metabolic factors on epigenetic mechanisms, and (3) assess the potential of using epigenetic markers to support diagnosis and prognosis. Translation of these findings may guide the development of molecular biomarkers and novel therapeutics for prevention or modification of epileptic disorders.
Introduction
Epilepsy is a prevalent neurological disorder affecting more than 50 million people worldwide (Ngugi and others 2010) . Patients suffer recurrent seizures, which are a result of aberrant, excessive, and synchronous firings of groups of neurons within the brain. Seizures originating from within a specific brain region are focal or localization-related, whereas generalized seizures occur simultaneously within both hemispheres of the brain. Seizures are dampened or reduced in many epileptic patients through treatment with antiepileptic drugs (AEDs). There are more than 20 AEDs in common use, each working to dampen brain excitability by boosting inhibitory or attenuating excitatory neurotransmission. However, in approximately 30% of epileptic patients, many AEDs fail to control seizures, and no current treatment options are disease-modifying or are known to prevent epilepsy in at-risk patients (Kwan and Brodie 2000) .
The cause of many epileptic disorders is unknown in an estimated 60% of patients. There are monogenic forms of epilepsy, often due to a mutation in an ion channel or component of excitatory or inhibitory neurotransmission.
However, these cases are relatively rare, and the contribution of genetics in the majority of patients is less clear (Thomas and Berkovic 2014) . Other forms of epileptic disorders can develop as a result of an earlier insult to the brain such as trauma or infection including temporal lobe epilepsy (TLE), the most common focal epilepsy in adults which is characterized by seizures frequently originating from the hippocampus and is often associated with select neuronal loss and gliosis termed hippocampal sclerosis (Blumcke and others 2013; Falconer 1974) . Most TLE patients are pharmacoresistant to AEDs and as a result, likely to undergo surgical resection as a treatment option for their seizures (Wiebe and others 2001) . Furthermore, beyond debilitating seizures, common comorbidities of this epileptic disorder include cognitive deficits, anxiety, and depression, making the search for the underlying cause and more effective treatments increasingly more urgent to improve patients' quality of life (Perrine and others 1995) . Still, the molecular causes leading to such impairments are poorly understood, and effective treatments are slow to emerge. Recently, epigenetic mechanisms have been linked to epilepsy and cognitive function. Since most of the work on uncovering epigenetic processes in epilepsy has been performed in the context of TLE, this review will focus on this epileptic disorder. However, it is likely that epigenetics also plays a role in various forms of epileptic disorders.
Epigenetic control of gene transcription has gained attention for its potential in the persistent and dynamic regulation of gene expression in the brain. Previously thought to be static in non-dividing, terminally differentiated cells, epigenetic mechanisms have been shown to remain dynamic and active in the mature human brain, and are necessary for the maintenance of essential neuronal function. Those same epigenetic modifications responsible for the regulation of normal brain activity are gaining attention as possible dysregulated systems within neuronal disorders including epilepsy. These biochemical signatures may represent potential biomarkers of epileptogenesis and epilepsy progression or serve as drug targets for the prevention or mitigation of epilepsy.
Epigenetics originally referred to heritable changes to the genome that did not involve direct changes to the genetic code. Now, epigenetics more broadly describes cellular processes that affect the medium to long-term readability and accessibility of the genome to transcription, thus influencing gene expression outside of direct changes made to the DNA sequence. Epigenetic mechanisms include DNA methylation at 5-methylcytosine (5-mC), hydroxymethylation at 5-hydroxymethylcytosine (5-hmC), changes to chromatin structure facilitated by posttranslational modification of histone proteins, and chromatin structural regulation by noncoding RNAs. Each of these categories of epigenetic processes has been shown to be altered in epilepsy. Efforts to determine whether these changes contribute to the development of the disease or are a response to the seizures themselves is still not fully known, and research has largely been driven by animal models of epilepsy. Epilepsy is, however, unusual among neurological disorders in having brain tissue available to study from living patients as a result of neurosurgical resections. Thus, researchers have been able to compare epigenetic changes observed in animal models of epilepsy to findings in human tissue. Animal modeling approaches have provided important corroborating evidence of epigenetic mechanisms while being a powerful validation of the available animal models.
Nevertheless, individual models suffer limitations of their own, and a key challenge has been to cross-compare findings. Thus, epilepsy is perhaps uniquely positioned to gain clinically relevant insights into the influence of epigenetics on gene expression through the use of multiple models and human tissue from living patients.
Epigenetic mechanisms have also been proposed to explain the development of pharmacoresistance in epilepsy patients, influencing the sustained patterns of gene expression that regulate AED uptake and mechanism of action. In the future, drugs inhibiting DNA methyltransferases (DNMTs) and histone lysine deacetylases (KDACs) could provide new treatments for patients unaffected by currently available anti-epilepsy medications. Not only are drugs acting on epigenetic processes currently available and in development for a variety of human diseases, but there is some evidence that one or more commonly used AEDs may act, in part, through epigenetic mechanisms. Most of the work identifying epigenetic changes in epilepsy has focused on DNA methylation. Recently, there has been exceptional interest in the role of microRNAs, especially where attention has also focused on their potential for use as biomarkers to support early diagnosis and prognosis in the clinic. In contrast, other aspects, such as histone modifications and long noncoding RNAs, have been less studied.
To determine if an epigenetic modification is causal to the development of epilepsy or a result of repeated seizures, it is most crucial to look at time points soon after the first status epilepticus event. Status epilepticus is the initiating injury event in many models of TLE characterized by a long convulsive seizure event. Following the initial seizure, both humans and rodents enter a latent period where they experience no seizures before developing epilepsy. However, not all patients will develop epilepsy after the initial seizure event. This latent period between status epilepticus and recurrent seizures is crucial to understanding the alterations in brain connectivity necessary to make a brain epileptic. Epigenetics is being discovered to be increasingly more important during this crucial time point before epileptogenesis. Epigenetic changes seen after status epilepticus but before prolonged epilepsy may have roles in making the switch to an epileptic brain state.
Epilepsy is associated with large changes in gene transcription that are exacerbated by altered metabolism. Network homeostatic regulation is achieved through a careful balance between excitatory and inhibitory synaptic inputs regulated through various intracellular metabolic processes, including glycolysis and interwoven methionine and adenosine-related pathways. Disorders, such as epilepsy, with aberrant cell metabolism will ultimately lead to changes in the overall epigenetic landscape of the cell, as metabolites fundamentally provide the donor substrates necessary for epigenetic modification (reviewed in Xu and others 2016). DNA and histone methylation are reliant on availability of metabolically produced methyl donors. Through this and several other pathways, metabolism can signal to the cell to control the underlying epigenetic landscape (Figure 1 ).
Epigenetic Mechanisms Implicated in Epilepsy

DNA Methylation
DNA methylation is one of the best understood epigenetic modifications. It occurs primarily in regions of DNA containing CpG sites, defined as cytosine residues directly next to guanine residues within the underlying DNA sequence. Methyl groups are added to DNA bases by enzymes known as DNMTs, which have been shown to have diverse and specific functions. DNMT3a and DNMT3b are largely associated with the addition of new methylation marks, whereas DNMT1 is primarily associated with maintenance of DNA methylation (Okano and others 1999) . Typically, after a region of DNA has been methylated, the transcription of the associated gene is repressed. Gene repression through DNA methylation is achieved by providing binding sites for transcription regulating proteins or preventing transcription factor binding. These factors will either promote compaction or opening of the DNA, making the corresponding sequence either more or less accessible to transcription by RNA polymerase. DNA methylation can be found anywhere within the genome, but methylation at promoter regions is especially interesting because of the regulatory potential for robust changes in transcription of the associated gene. Previously considered to be a stable mark, it is now known that DNA methylation is dynamic, and methyl groups can be modified or removed from DNA residues through the activity of certain enzymes including GADD45B (Ma and others 2009) .
Alterations in DNA methylation has been observed in TLE, with several genome-wide studies supporting evidence that epilepsy progression is accompanied by largescale methylome changes. Accompanying genome-wide methylation changes is evidence supporting dynamic protein expression of DNA modifying enzymes in TLE human tissue. For example, evidence that DNMT3a and DNMT1 are up-regulated in TLE hippocampal tissue and are especially prevalent in neuronal cells, suggests that de novo DNA methylation and its maintenance are involved in human TLE (Zhu and others 2012) . Injuries associated with inciting TLE have been reported to promote a lowered state of methylation, suggesting a switch toward increased gene transcription. In contrast, research evidence shows that the chronic epileptic state associated with overall global hypermethylation of the genome. An initial study of DNA methylation in a rat pilocarpine model demonstrated that global increases in methylation inversely correlated with a decrease in the expression of some genes (Kobow and others 2013b) . Intriguingly, an amygdala stimulation model of TLE showed a decrease in promoter methylation that correlated with an increase in gene expression (Debski and others 2016) . These studies underscore the importance of distinguishing global DNA methylation and promoter methylation changes as it relates to gene transcription silencing and the role of DNA methylation in epilepsy development and progression.
Another interesting aspect of the DNA methylation study performed by Debski and colleagues compared the pilocarpine, amygdala stimulation, and traumatic brain injury models of epilepsy and found no commonly differentially methylated genes or enrichment of similar gene ontologies. However, the three epilepsy models did share seven similarly up-regulated genes (Debski and others 2016) . Interestingly, a genome-wide methylation study in the kainate model of TLE identified 321 differentially methylated genes, predominately hypomethylation events, with an inverse correlation between decreased DNA methylation and increased gene expression (Miller-Delaney and others 2012). Of note, there was little overlap among the studies described above in the specific genes reported undergoing changes. Collectively, these findings indicate a strong influence of etiology and model-specific regulation of methylation.
DNA methylation has been found to be altered for 146 genes in the hippocampus of TLE patients defining hippocampal sclerosis, most of which were found to be hypermethylation events. Gene ontology analysis revealed that these genes were involved in neural development, differentiation, remodeling, and maturation. Notably, there appeared to be a weak association between methylation state and expression of the affected gene (Miller-Delaney and others 2015) . Interestingly, methylation at microRNA gene regions was also investigated, suggesting that expression of several microRNAs were highly sensitive to methylation at the transcriptional start site and putative promoter regions (Miller-Delaney and others 2015) .
DNA methylation at 5-mC can be further modified to 5-hydroxymethylcytosine (5-hmC) by ten-eleven translocation (TET) enzymes which mediate the oxidation of 5-mC marks to 5-hmC (Tahiliani and others 2009) . The role of 5-hmc in the brain is of exceptional interest from a neuroscience perspective because this mark is abundantly present in the brain, indicating a likely prevalent role as a major epigenetic regulator of neuronal activity (Kriaucionis and Heintz 2009; Munzel and others 2010) . Genome wide analysis shows that 5-hmC can be present in areas of both transcriptional repression and activation, though this mark is typically associated with enhanced gene transcription (Wen and others 2014; Wu and others 2011) . Hydroxymethylated regions can serve as binding sites for proteins acting as regulators of transcription (Spruijt and others 2013) . Notably, within the brain, the methyl binding protein MeCP2 was shown to preferentially bind to 5-hmC marks, supporting a major role for MeCP2 in the regulation of the neural transcriptome (Mellen and others 2012) .
DNA hydroxymethylation remains understudied in the context of epilepsy in comparison to DNA methylation. This discrepancy was, however, recently addressed. Global levels of 5-hmC were found to be decreased in the hippocampus in areas CA3 and the dentate gyrus in a rodent kainate model of status epilepticus (Parrish and others 2013) . Additionally, TET1, the protein responsible for the addition of hydroxymethylation, was found to be down-regulated in the hippocampus following acute seizures (Kaas and others 2013) . Though a global role for 5-hmC and its regulatory enzyme TET1 has been shown in the epileptic hippocampus, at present, DNA hydroxymethylation has not been mapped at a gene-specific level within epilepsy. Thus, it is uncertain how dynamic these changes are and whether demethylation events affect the same or different regions of the genome as methylation in epilepsy. Moreover, using current technologies, it is often difficult to differentiate 5-mC and 5-hmC marks, meaning it is very likely then that 5-hmC levels are also responsively changing in bisulfite sequencing studies showing alterations in 5-mC with epilepsy (Huang and others 2010; Jin and others 2010).
As DNA methylation and hydroxymethylation regulate the genome through either allowance or prevention of regulatory protein binding, the role of methyl binding proteins is thought to modulate epilepsy progression in addition to basal methylation changes (Li and others 2015) . Methyl binding proteins bind to regions of methylated DNA and can aide in either transcriptional repression or activation of the bound sequence. The influence of dysregulated or dysfunctional methyl binding proteins on seizure activity is perhaps most obvious in epilepsyrelated neurological disorders such as Rett syndrome. Rett syndrome is caused by genetic mutations in the methyl binding protein MeCP2, and patients with Rett syndrome commonly experience epileptic seizures as a comorbidity of the disorder. One of the effects of reduced MeCP2 is bidirectional alterations in expression of genes involved in neurotransmission and various neuromorphological phenotypes including reduced dendritic complexity which likely promote the excessive excitatory input to neurons that can result in seizures (reviewed in Lyst and Bird 2015) .
MeCP2 is known to be associated with hypermethylation at the RELN promoter, a region with increased methylation in TLE. The RELN gene encodes a protein (reelin) secreted from Cajal-Retzius cells critical to cell positioning, including the densely-packed granule cell layer of the dentate gyrus. This suggests the role of methyl binding proteins in the dysregulation of this extracellular matrix protein encoding gene associated with epilepsy (Kundakovic and others 2007) . In addition to MeCP2, the methyl binding protein MBD2 was found to be implicated in epilepsy through binding to specific CpG sites involved in the up-regulation of the sodium channel protein coding gene Scn3a. As sodium channels help in the regulation of neuronal excitation, this suggests a possible mechanism for Scn3a dysregulation seen in epilepsy through interactions of DNA demethylation and MBD2 (Li and others 2015) .
Posttranslational Modifications of Histones
DNA is condensed into chromatin within cell nuclei and wrapped around proteins called histones. The single unit of chromatin is called the nucleosome, and consists of approximately 146 nucleotides wrapped around a histone core. The histone core is an octamer composed of 4 histones, typically H2A, H2B, H3, and H4. Histones can be modified on their N-terminus, commonly on lysine or arginine residues, and these histone tail modifications can promote the transformation of chromatin conformation into a readily accessible and heavily transcribed configuration called euchromatin, or they can condense the chromatin into tightly wound heterochromatin typically associated with areas of transcriptional repression. The change from hetero-to euchromatin depends on both the type of modification being added, what histone is being modified, and the location of that modification on the N-terminal histone tail. Typically, the addition of acetyl or phosphate groups physically alters the structure of chromatin, making the DNA more easily accessible to transcription by polymerase. Alternately, methylation marks act as modulators of transcription through permitting the binding of proteins that either repress or activate transcription of the bound DNA via either polymerase recruitment or exclusion (reviewed in Lubin 2012) .
It is noteworthy that there are AEDs in use that target histone modifications. This includes valproic acid, one of the most commonly prescribed drugs for the treatment of epilepsy. Valproic acid is known to have lysine deacetylase (KDAC) inhibiting properties, and interestingly valproic acid also affects DNA methylation at specific genes within the hippocampus (Aizawa and Yamamuro 2015; Detich and others 2003; Gottlicher and others 2001; Milutinovic and others 2007) . Because of the drug's known KDAC inhibiting properties, histone modification changes were accordingly targeted early on in the study of epilepsy epigenetics, most notably with the study of histone acetylation marks. Acetylation of histone H4 was shown to be altered in the hippocampus of rats at the BDNF and GluR2 genes following status epilepticus, associated with regulation of the resulting mRNA expression (Huang and others 2002) . Since then, the study of altered histone modifications in TLE has expanded to include changes in histone H3 phosphorylation (Crosio and others 2003; Sng and others 2006; Zybura-Broda and others 2016 ). However, other tested KDAC inhibitors do not appear to have anticonvulsive effects suggesting that this property is probably not important for the seizure-suppressive effects of valproic acid (Hoffmann and others 2008) . While there is limited functional evidence that histone acetylation is required for epileptogenesis, one study suggests that loss of the lysine deacetylase KDAC4 results in the development of later-life epilepsy in mice (Rajan and others 2009) .
Epilepsy is a disorder characterized by altered neuronal excitability, including alterations in glutamate receptors following status epilepticus. This process is known to be epigenetically controlled through a decrease in histone H4 acetylation at the glutamate receptor encoding gene GluR2, lowering total mRNA expression. Likewise, acetylation regulates several processes relevant to the progression of epilepsy, including increased H4 acetylation at the BDNF P2 promoter following status epilepticus (Huang and others 2002) , and H4 acetylation-driven activation of c-fos and c-jun expression during epileptogenesis within the hippocampus (Sng and others 2006) . Along with histone acetylation, histone phosphorylation plays a role in the transcriptional regulation of epilepsyassociated genes. Coupled to H4 acetylation, H3S10Ph was found to be initiating up-regulation of c-fos in the dentate gyrus (Sng and others 2006; Taniura and others 2006) , and H3S10Ph has been implicated in the regulation of hippocampal Mmp-9, a transcript encoding an extracellular matrix protein, during epileptogenesis (Zybura-Broda and others 2016).
As opposed to histone acetylation, which is an activator of gene transcription, histone methylation can either enhance or repress gene transcription, depending on the location and number of modifications per amino acid residue. Histone lysine methylation, in particular, has been widely studied and annotated as a part of efforts to understand the histone code. Histone methylation changes have not yet been thoroughly explored in the context of epilepsy. However, a recent study examining the polycomb repressive complexes 1 and 2 (PRC1 and PRC2) which regulate trimethylation at histone H3 at lysine 27 (H3K27me3), a well-annotated posttranslational histone modification corresponding with transcriptional repression, found H3K27me3 influenced the expression of matrix metalloproteinase-9 during epileptogenesis (Zybura-Broda and others 2016).
Histone methylation has been shown to play critical roles in neuronal function and is known to be highly regulated in processes such as learning and memory (Gupta and others 2010; Gupta-Agarwal and others 2012) . Since histone modifications are crucial in the regulation of chromatin structure, and therefore the regulation of gene expression, these dynamic changes could play an important role in epilepsy progression. As environmental cues change, so too can histones be rapidly modified to better adapt the cell to a new environment. Histone modifications show promise in the regulation of chromatin structure and gene expression during epilepsy (Table 1) . However, this area requires further study.
Non-coding RNAs
Non-coding RNAs comprise a diverse class of regulatory molecules that broadly includes small noncoding RNAs such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) including circular RNAs, long interspersed elements, and pseudogenes (reviewed in St Laurent and others 2015). MicroRNAs have gained particular interest in epilepsy as various miRNAs are dysregulated in human TLE. Functional studies have reported powerful seizure-regulating effects of at least a dozen different miRNAs to date. Biofluids from patients with epilepsy have also been reported to contain altered levels of certain miRNAs supporting their potential use as putative biomarkers of epilepsy. For a recent review on this topic, the reviewer is referred elsewhere (Henshall and others 2016) , and interested readers can search EpimiRBase for a comprehensive list of miRNAs associated with epilepsy (Mooney and others 2016) .
Unlike miRNAs, long non-coding RNAs (lncRNAs) have not yet gained much attention within the epilepsy field, and they require further study. LncRNAs are around 200 nucleotides or more in length, typically do not encode for protein, and act through a variety of mechanisms to impact epigenetic modifiers and gene transcription. LncRNAs are gaining attention in the regulation of several neuronal mechanisms including the regulation of cognition and memory (reviewed in Butler and others 2016). A genome-wide lncRNA profiling study found differential regulation of lncRNAs in both the pilocarpine and kainate acid models of TLE, suggesting lncRNAs act as regulators of inflammation and neuronal differentiation pathways in the epileptic brain . Interestingly, the nuclear lncRNA Neat1 is down-regulated following seizure activity and aids in the regulation of neuronal excitation, notably through interactions with potassium channels (Barry and others 2017) . Supporting the involvement of lncRNAs in the maintenance of neuronal excitation, the lncRNA BC1 comprises the balance of neuronal excitation and repression through transcriptional inhibitory mechanisms with seizures (Zhong and others 2009), and Malat1 has been reported to aid in synaptogenesis (Bernard and others 2010) .
With regard to the methylation hypothesis of epilepsy progression, a recent study has looked at the methylation of non-coding RNA genes in the blood of patients with TLE. LncRNA promoters were found to be mostly hypermethylated, and these lncRNAs targeted genes in pathways relevant to pharmacoresistance and neuronal signaling (Xiao and others 2017) . This idea complements the differential methylation of miRNA and lncRNA genes found in epileptic human hippocampal tissue (MillerDelaney and others 2015) . These studies show the importance of furthering the investigation of this transcriptional regulatory mechanism in epilepsy. In addition to elucidating potential involvement in molecular mechanisms of epilepsy development, lncRNAs represent potential drug targets for the treatment of epilepsy. This potential gains further support as administration of an antagoNAT resulted in up-regulation of the sodium channel protein SCN1A and reduced seizures by targeting endogenous NAT (natural antisense transcript) RNAs in a model of the epilepsy-related disorder Dravet syndrome (Hsiao and others 2016) (Table 2, Figure 2 ).
The Role of Metabolism in the Epigenetic Regulation of Epilepsy
Glucose Utilization in Epilepsy
It is well-established that metabolism plays an important role in neuronal network stability and that metabolic dysfunction is a strong influence in certain epilepsy syndromes. Glucose is the brain's primary source of energy, and treatments targeting glucose metabolism show promise in epilepsy. The ketogenic diet is designed to resemble fasting and results in ketosis, an increase of ketone body metabolites. This provides neurons with an alternate energy source to glucose. The ketogenic diet has long been used to help reduce seizures in pharmacoresistant patients and continues to be popular for refractory epilepsy in children. Likewise, the ketogenic diet is known to effectively treat GLUT1 deficiency syndrome, a disorder characterized by decreased GLUT1 transporter expression and is accompanied by seizures (Klepper and others 2005) .
The mechanism by which the ketogenic diet works is not fully understood. It has been shown that ketones themselves do not have an antiepileptic effect in studies using direct administration of ketones to hippocampal slices; however, in vivo administration results in seizure reduction. It has been suggested that the ketones could act by alteration of glutamate signaling pathways and that the effect of the ketogenic diet is linked to extracellular glucose levels (Kawamura and others 2014; Kawamura and others 2016). Inhibition of the glycolytic pathway through the administration of 2-deoxy-d-glucose shows an 
Resected epileptic hippocampus
MMP-9
Decrease n/a (Zybura-Broda and others 2016)
Peripheral blood n/a Increase at lncRNA and miRNA promoters n/a (Xiao and others 2017) Peripheral blood n/a Global increase n/a (Long and others 2017) CA1 = cornu ammonis region 1; CA3 = cornu ammonis region 3; DG = dentate gyrus; n/a = not applicable; PILO = pilocarpine; TBI = traumatic brain injury.
anticonvulsant effect (Stafstrom and others 2008; Stafstrom and others 2009) . These findings suggest that dysregulated glucose and its metabolic intermediates play a crucial role in epilepsy progression. Glycolysis feeds into the citric acid cycle to ultimately produce glutamate and other important neurotransmitters (Olsen and Sonnewald 2015) . Alterations in the way neurons metabolize glucose and harvest this energy could result in the large changes in gene expression that lead to the sudden, spontaneous electrical firings seen with epileptic seizures.
Methionine
Methionine metabolism results in the production of the methyl-donor S-adenosyl methionine (SAM), making it an important regulatory metabolite in the pathway of DNA methylation. The reaction responsible for the addition of SAM's methyl group to another molecule results in the cycling of SAM to S-adenosyl-l-homocysteine (SAH). An increase in the concentration of intracellular SAM can promote DNA and histone methylation, and in turn, high SAH levels prevent further DNA and histone methylation (reviewed in Berger and Sassone-Corsi 2016) . Within the study of epilepsy, SAM has been shown to have antiepileptic properties (Dhediya and others 2016) . SAM metabolism results in the production of neuroprotective adenosine, possibly contributing to these anti-seizure effects. However, SAM can also act through involvement in transmethylation pathways, serving as a methyl donor for DNA and histones. Direct methionine (met) infusion results in a global increase in methylation, and artificial overexpression of DNA methylation through methionine injection can act as a valuable tool in the study of DNA methylation interactions in epilepsy (Parrish and others 2015) .
The hippocampus, a brain region important for memory formation, is frequently the site of pathology and ictogenesis in TLE. Accordingly, patients often experience cognition and memory difficulties as a comorbidity of the disorder. The BDNF gene has been known to be important in memory formation and dysregulated with epilepsy (Lubin and others 2008; Martinez-Levy and others 2016). Parrish and others observed an increase in activity-dependent memory formation associated with increased levels of BDNF in the rat kainate model of TLE. Supplementation with methionine both decreased BDNF transcript and improved the memory impairment in epileptic rats, suggesting a role for DNA methylation in epilepsy associated memory decline (Parrish and others 2015) . Methionine is a component of methionine sulfoximine (MSO), a chemical that has been known to induce seizures for decades; however, its mechanism of action has not been described. MSO is molecularly similar to glutamate, suggesting action through inhibition of glutamate receptors (Campbell and others 1951; Cloix and Hevor 2009) . Alternatively, it has been reported that MSO inhibits glutamine synthetase, leading to neuronal activation through disruption of normal glutamine metabolism (Albright and others 2016; Richard and Hevor 1995) .
Adenosine
Adenosine acts as an endogenous anticonvulsant, and adenosine is a well-defined inhibitory neuromodulator within the brain acting on A1 receptors at synapses. Inhibition at epileptic synapses through adenosine administration suggests that network excitability is controlled by adenosine cycling (reviewed in Boison 2016) . Adenosine is involved in several pathways at an intracellular level being an essential component of ATP/ ADP, the primary energy unit of cells, and involved in reduction and oxidation as a component of NADH. Interestingly, adenosine aids in the regulation of DNA methylation through modulation of SAM/SAH cycling, and augmentation with adenosine is known to both prevent epileptogenesis and decrease global DNA methylation in the hippocampus (Williams-Karnesky and others 2013). Since methylation changes with epileptogenesis have been well documented, it is possible that adenosine's anticonvulsant properties are at least in part due to the regulation of this epigenetic pathway.
Maintenance of adenosine is achieved through regulation by adenosine kinase, and the balance of adenosine and adenosine kinase is a crucial factor in epilepsy development. This regulation is especially relevant to epilepsy within astrocytes as adenosine kinase is abundant in astrocytes. Astrogliosis is commonly seen in epileptic tissue, suggesting a strong role for astrocytic metabolism in epilepsy (Li and others 2008) .
The biochemical interactions between the pathways of adenosine and methionine metabolism conceptually elucidate the contribution of maladaptive changes in brain biochemistry as a major contributing factor to epilepsy development. In association with epilepsy and alterations in adenosine and methionine pathways, there is evidence for dynamic changes in cofactors utilized by epigenetic modifiers and epigenetic substrates. However, whether aberrant metabolism is the root source of the sudden seizures, or instead the result of epileptic activity and the underlying continuous editing of the epigenome is still uncertain. Because of the defined interwoven nature of metabolism and epigenetics, the role of metabolism in the study of epilepsy epigenetics cannot be ignored.
Epigenetic and Metabolic Control of Glutamate Transmission in Epilepsy
Glutamate is an important neurotransmitter, and regulation of glutamate and its metabolic intermediates is crucial to epilepsy progression through their involvement in the control of neuronal excitability. In addition to glutamate, the regulation of glutamate receptors has a strong role in epilepsy. The glutamate receptor encoding genes Gria2 and GluR2 have been shown to be associated with epileptic tissue. Furthermore, these genes are known to be epigenetically regulated in the context of epilepsy through both histone acetylation and DNA methylation changes (Huang and others 2002; Machnes and others 2013) .
In TLE, glutamine synthetase (GS), the molecule responsible for the synthesis of the neurotransmitter glutamate, has been shown to be down-regulated in hippocampal astrocytes (Dhaher and others 2015) . As astrogliosis is a common hallmark of epileptic foci in the brain, this suggests that GS dysregulation in these cells may contribute to dysregulation of glutamate homeostasis. Further supporting the importance of glutamine synthetase regulation's contribution to epilepsy progression, haploinsufficiency of GS increases susceptibility to febrile seizures in a mouse model (van Gassen and others 2009). It is clear that a balance of GS is crucial to the maintenance of healthy brain activity, and regulation of this pathway could provide an important link between epigenetic processes and cellular metabolism.
Putative Epigenetic Biomarkers for Early Diagnosis of Epilepsy
There are currently no well-annotated molecular biomarkers for epilepsy to aid in the early diagnosis of abnormal epileptic associated activity within the brain.
Such a biomarker would be transformational since epilepsy is associated with high misdiagnosis rates and the best diagnostic tool-electroencephalography (EEG)-is slow and technically demanding. Moreover, many patients with epilepsy have a normal EEG and patients without epilepsy can have an abnormal EEG. Although EEGs are capable of monitoring the abnormal activity seen with epilepsy, the patient must be experiencing epileptic activity at the time of reading to make it a useful tool in the diagnosis of epilepsy. Currently, a reliable biomarker could help in getting patients treatment before further progression of the disorder does irreversible damage to the brain. The detection of biomarkers could lead to the development and use of anti-epileptogenic drugs that will target the underlying cause of epilepsy before patients succumb to recurrent seizures.
In the search for new biomarkers, it is important to keep in mind accessibility in the clinic. The biomarkers should be easily read with common clinical lab equipment, and ideally, could be screened for during routine tests such as blood or urine samples. Because of this, molecular mechanisms underlying epileptogenesis, including epigenetic mechanisms, are then key focal points in the study and identification of epileptic biomarkers because they can change with the onset of the disorder and can be present in biofluids collected from patients.
MicroRNAs are the leading candidates in the search for epigenetic biomarkers for the early detection epilepsy due to their differential expression and ready accessibility in blood samples. Recently, mir-134 levels in serum have been shown to have promise for easy detection in epilepsy patients (Spain and others 2015) . Likewise, serum mir-4521 could be a potential biomarker for patients with refractory epilepsy (Wang and others 2016d) . Several miRNAs, notably mir-301a-3p, are shown to be differentially expressed in serum between drug resistant and drug responsive patients . Therefore, miRNAs in serum could be used in the clinic to detect both epilepsy and likelihood of drug resistance early.
DNA methylation is proving to be a key molecular mechanism of epileptogenesis and could be invaluable as a means to detect epilepsy progression. Furthermore, the DNA methylation status in TLE patients can easily be assessed, as it has been demonstrated to be differentially regulated in TLE patient blood (Long and others 2017; Xiao and others 2017) . Therefore, as testing in the clinic improves, it is possible that DNA methylation levels of certain genomic regions can be tested for as a biomarker of epilepsy progression and could potentially be used to inform clinicians of the most effective anti-epileptogenic drugs to use to halt the further development of epilepsy.
Therapeutic Prospects for the Future
One of the challenges facing treatment options for epileptic disorders is determining the optimal time window for intervention or preventative care. For example, if reliable biomarkers are discovered for the detection of epilepsy onset prior to structural neuronal damage due to chronic seizures, this would be an ideal time window to begin intervening treatments. However, the availability of this optimal time window is often not a reality, as most patients diagnosed with epilepsy have already experienced chronic seizure episodes and damage to neuronal networks. Thus, the goal to identify new biomarkers early on to prevent further epilepsy progression and to lessen seizure severity and frequency remains a challenge. The epigenetics field represents the potential for the discovery of new molecular biomarkers and antiepileptogenic drug targets, and uncovering mechanisms underlying epileptogenesis.
With the development of new technology, researchers and physicians can more accurately evaluate epigenetic mechanisms that make studying the role of epigenetics in epilepsy more attainable. There are new molecular, bioinformatic, and surgical tools developed to allow us to increase our understanding of the underlying mechanisms involved in the development of epilepsy. One such tool is the EpiMiRbase database, which will prove to be increasingly relevant with the number of miRNAs associated with epilepsy rising (Mooney and others 2016) . The development of new molecular tools such as CRISPR, optogenetics, and DREADDS can also improve epilepsy research by allowing the targeting of specific genes, epigenetic modifications, cell types, and receptors in rodent models of epilepsy. Likewise, new surgical tools are improving the diagnosis of seizures. Utah arrays are surgically implanted into the brain and help to pinpoint the source of focal epilepsies to allow physicians to treat the pharmacoresistant patients more specifically through surgical resection (Fernández and others 2014) . As new techniques and technologies are developed to improve the diagnosis and study the progression of epilepsy, our understanding of this disorder improves, and we come closer to the development of new treatments for patients.
Conclusions
The study of epigenetics in epilepsy is a new field with opportunities for researchers and physicians alike. Through the use of human tissue and animal models, it has been shown that epigenetic mechanisms are dynamically regulated during the progression of epilepsy. Genome-wide DNA methylation changes are observed in epileptic tissue, with the potential for altering transcription of genes important for the switch to an epileptic state (Debski and others 2016; Kobow and others 2013b; Miller-Delaney and others 2012) . Chromatin structure is altered in epilepsy through changes in histone modifications, notably histone acetylation. Because of the global shift in DNA methylation, it is likely that histone methylation is dynamically changing as well, and histone methylation remains an area warranting further study in the context of epilepsy. LncRNAs and miRNAs involved in the regulation of the chromatin state surrounding gene regions are beginning to show a promising role in the development of epilepsy. Excitingly, this translates into the likelihood that ncRNAs hold promise for use as potential biomarkers for early detection of epilepsy in the clinic.
Epilepsy is a disorder that is highly interwoven with aberrant metabolism. Because of the fundamental nature of metabolites in providing donor substrates for epigenetic modifications, it is inevitable that epileptic changes in metabolism regulate the epigenetic landscape of the brain. Methionine and adenosine metabolic pathways play considerable roles in the development of epigenetic marks with epilepsy. The role of methionine in epilepsy has been shown through the pro-convulsant effects of MSO administration. Notably, methionine metabolism is crucial in the regulation of intracellular SAM levels, affecting DNA methylation through the regulation of methyl donation. In contrast to methionine, adenosine administration has been shown to have an anticonvulsant effect. However, adenosine also aids in the regulation of SAM through feedback into SAM/SAH cycling. Metabolism of both these molecules has been shown to affect epilepsy progression and aid in the regulation of global methylation within the cell.
As epilepsy is a disorder characterized by hyperexcitability, dysregulation of the excitatory neurotransmitter glutamate and glutamate receptors is critical to the development of epilepsy. Not only are glutamate receptors differentially expressed in TLE, but this regulation has been shown to be epigenetically driven (Huang and others 2002) . In the absence of glucose, neurons can use ketones as an energy source. Glucose metabolism is highly linked to epilepsy, and switching to ketone utilization through the ketogenic diet is shown to have an anti-seizure effect in some epilepsy-related disorders. Likewise, supplementation with the glycolysis derivative 2-deoxyglucose has some anti-epileptic properties suggesting that glucose metabolism pathways could serve as new targets for future AEDs (Stafstrom and others 2008) .
Many patients are resistant to current AEDs. Therefore, it is critical that new drugs with the potential to benefit pharmacoresistant patients are developed. Epigenetic pathways are strong candidates for the future of AED targets, as several epigenetic pathways are altered in epilepsy. Drugs targeting epigenetic mechanisms are already in use, and they are of high interest for potential treatments for several diseases and disorders including epilepsy. DNMT and KDAC targeting drugs could show potential in epilepsy treatment as DNA methylation and histone acetylation show robust changes with epilepsy. Likewise, ncRNA targeting drugs have the potential to target several dysregulated pathways at once.
Beyond better treatments for epilepsy, the discovery of biomarkers could serve in the diagnosis of epilepsy. There are currently no biomarkers in use for early identification of epilepsy or pharmacoresistance. However, miRNAs show strong promise for use as biomarkers because of their availability in biofluids and differential expression in epilepsy, and they could soon be used for early detection and aided diagnosis in the clinic. As we further elucidate the epigenetic regulatory mechanisms underlying epilepsy, there is great potential for translational applications for patients.
